Impaired brachial endothelial function in patients with primary anti‐phospholipid syndrome

Although the precise pathophysiology of thrombosis is unknown in primary anti‐phospholipid syndrome (PAPS), it is assumed that autoantibodies developed against endothelial cells and platelets might be one of the primary mechanisms. However, whether interaction between autoantibodies and endothelium leads to an impaired vasodilator response has not been investigated yet. In this study, we aimed to investigate the endothelial functions in patients with PAPS. Thirty‐one patients with PAPS (22 female, nine male, mean age: 34.6 ± 8.9 years) and 27 age‐ and sex‐matched, healthy controls were included in the study. Brachial artery responses to reactive hyperaemia (endothelium‐dependent dilatation) [EDD] and sublingual nitroglycerine (endothelium‐independent dilatation) [EID] were measured by using high‐resolution vascular ultrasound both in patients with PAPS and in the controls. The results were expressed as percentage of change in baseline values. Regarding cardiovascular risk factors, there was no significant difference between the two groups. EDD in patients with PAPS was significantly lower than those of controls (6.9 ± 4.9 vs. 14.8 ± 4.1%; p < 0.0001). EID measurements were not significantly different between the groups. In the PAPS group, EDD in patients with arterial involvement (17 patients) was significantly lower than those of patients with venous involvement (12 patients) (4.6 ± 3.9 vs. 7.4 ± 4.1%; p = 0.02).

[1]  Y. Shoenfeld,et al.  Autoantibody-mediated atherosclerosis. , 2002, Autoimmunity reviews.

[2]  R. Asherson,et al.  Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. , 2002, The Journal of rheumatology.

[3]  M. Armani,et al.  Are Antiphospholipid Antibodies an Independent Risk Factor for Atherosclerosis? , 2002, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[4]  S. Verma,et al.  Fundamentals of endothelial function for the clinical cardiologist. , 2002, Circulation.

[5]  F. Miranda,et al.  Brachial endothelial function is impaired in patients with systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[6]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[7]  Y. Shoenfeld,et al.  Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome. , 2001, Rheumatic diseases clinics of North America.

[8]  D. Shome,et al.  The association of antiphospholipid antibodies with ischaemic stroke and myocardial infarction in young and their correlation: a preliminary study. , 2001, The Journal of the Association of Physicians of India.

[9]  J. Kooner,et al.  Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. , 2001, Journal of the American College of Cardiology.

[10]  G. Hughes,et al.  Systemic Endothelial Cell Markers in Primary Antiphospholipid Syndrome , 2000, Thrombosis and Haemostasis.

[11]  J. Townend,et al.  Suppression of Inflammation in Primary Systemic Vasculitis Restores Vascular Endothelial Function: Lessons for Atherosclerotic Disease? , 2000, Circulation.

[12]  F. Romero,et al.  Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis , 2000, Lupus.

[13]  Pojen P. Chen,et al.  An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. , 1999, Arthritis and rheumatism.

[14]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[15]  Xiaowei Liu,et al.  Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. , 1999, Circulation.

[16]  Y. Shoenfeld,et al.  Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. , 1998, Circulation.

[17]  M. Khamashta,et al.  Endothelial Cells as a Target for Antiphospholipid Antibodies: Role of Anti‐Beta 2 Glycoprotein I Antibodies , 1997, American journal of reproductive immunology.

[18]  J. Hanly,et al.  Beta 2-glycoprotein I and anticardiolipin antibody binding to resting and activated cultured human endothelial cells. , 1996, The Journal of rheumatology.

[19]  I. Scharrer,et al.  Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.

[20]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[21]  E. Harris,et al.  Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. , 1990, American journal of clinical pathology.

[22]  K. Welch,et al.  Cerebrovascular and neurologic disease associated with antiphospholipid antibodies , 1990, Neurology.

[23]  Harris En A reassessment of the antiphospholipid syndrome. , 1990 .

[24]  R. de Caterina,et al.  Prevalence of anticardiolipin antibodies in coronary artery disease. , 1990, The American journal of cardiology.

[25]  A. Hamsten,et al.  ANTIBODIES TO CARDIOLIPIN IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION: AN ASSOCIATION WITH RECURRENT CARDIOVASCULAR EVENTS , 1986, The Lancet.

[26]  G. Hughes,et al.  The anticardiolipin syndrome. , 1985, The Journal of rheumatology.

[27]  J. Fernandes,et al.  LACTATE AS ENERGY SOURCE FOR BRAIN IN GLUCOSE-6-PHOSPHATASE DEFICIENT CHILD , 1982, The Lancet.

[28]  G. Hughes,et al.  Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. , 1998, The Journal of rheumatology.

[29]  D. D’cruz,et al.  Antibodies, thrombosis and the endothelium. , 1994, British journal of rheumatology.

[30]  C. A. Bowles Vasculopathy associated with the antiphospholipid antibody syndrome. , 1990, Rheumatic diseases clinics of North America.

[31]  E. Harris,et al.  A reassessment of the antiphospholipid syndrome. , 1990, The Journal of rheumatology.